metrorrhagia/triglyceride

This 2-year study compared Mesigyna(R) administered to 49 pre-menopausal women between 38 and 50 years, to 99 women fitted with an IUD (Nova-T). A complete lipoprotein assessment was carried out before treatment and at 6, 12, and 24 months of treatment. A bone densitometry was performed on half of

This six-cycle, multicenter, open-label, randomized study compared the clinical experience of two low-dose oral contraceptives (OC): a triphasic OC containing norgestimate (NGM) and 35 micrograms ethinyl estradiol (EE) (Ortho Tri-Cyclen) and a monophasic OC containing norethindrone acetate (NETA)

The clinical experience with a combined oral contraceptive (COC) containing 150 micrograms desogestrel and 30 micrograms ethinylestradiol is reviewed. Fourteen clinical trials have been reported involving over 44,000 women for more than 190,000 cycles. None of the 17 pregnancies which occurred

Healthy, non-smoking, normotensive, well-motivated young women were assigned at random to one of four different, commercial, low-estrogen, oral contraceptive products. Measurements of biochemical parameters were made on blood specimens collected from fasting subjects twice during the late

Healthy, nonsmoking, normotensive, well-motivated young women were assigned at random to one of four different commercial, low-estrogen oral contraceptives. Measurements of biochemical parameters were made on two blood specimens collected from fasting subjects late in the pretreatment cycle, then

A clinical study was performed with a new progestogen, desogestrel, in a 0.15 mg dose associated with 0.03 mg of ethinylestradiol and was administered cyclically during 21 days; 632 cycles were evaluated in 56 women. Side-effects were scarce and generally of a mild nature. Monthly bleeding was

In a prospective study 40 perimenopausal women with climacteric complaints between 45 to 52 years of age were examined. Twenty three (100%) were assigned to treatment with hormonal replacement therapy (Climen fy Schering-estradiol valerate cyproteron acetate) for 6 months. The therapy had to be

A prospective, double-blind clinical study has been carried out in 90 chinese women with postmenopausal period covering 0.5 to 21 years by administering a synthetic long-acting estriol derivative-nylestriol in the regimen of 2 mg every 2 weeks for 1 year (49 treated and 41 placebo). The result were:

The purpose of the study was to evaluate the efficacy and safety of a sequential regimen of estrogen-progestin addition to GnRH agonist suppression in ovarian hyperandrogenism. Eight patients presenting with a polycystic ovary syndrome were treated with an sc implant of GnRH agonist every 4 weeks

In a group of 25 post menopausal women mean age 57.2 years, treatment with Estriol vagina cream (Ovestin cream from Organon-Holland) gives rise (but within normal limits) to cholesterol, triglycerides and HDL-cholesterol, the protective factor against M. I. A rise in glycohemoglobin (HbA1C)

Transdermal systems for oestrogen therapy in the menopause have become very popular. The compliance, however, is impeded by the cyclic addition of oral progestins which leads to monthly withdrawal bleeds. In this pilot study a skin patch releasing 0.05 mg oestradiol and 0.25 mg norethisterone

In a study of 42 girls, aged 12 to 15 years, including 27 patients with dysfunctional uterine bleedings (DUB) and 15 normal controls, the levels of glucose, total lipids, beta-lipoproteins, total cholesterol, as well as beta-lipoprotein, triglycerides, nonesterified fatty acid (NEFA) cholesterol and

A prospective exploratory study was carried out on lipid metabolism (41 women); as well as efficacy, acceptability and safety on another 190 women who all were using a combined oral contraceptive pill (OC) containing 30 micrograms Ethinyl oestradiol and 150mg Desogestrel (Marvelon) over a period of

The performance of a new low-dose oral contraceptive (Mercilon) containing only 20 micrograms ethinyloestradiol combined with 150 micrograms desogestrel is reviewed. Eight multicentre clinical trials have been completed and provide information on 10,672 women studied over 73,477 cycles. The high